1,406
Views
3
CrossRef citations to date
0
Altmetric
Articles

Rare genetic variants prioritize molecular pathways for semaphorin interactions in Alzheimer’s disease patients

, , , , , , , , , , , , , , & show all
Pages 1256-1262 | Received 27 Apr 2021, Accepted 01 Aug 2021, Published online: 23 Aug 2021

References

  • Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357–367.
  • Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048–1056.
  • Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain. 2009;132(5):1355–1365.
  • Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.
  • Mufson EJ, Binder L, Counts SE, et al. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 2012;123(1):13–30.
  • Vijayakumar A, Vijayakumar A. Comparison of hippocampal volume in dementia subtypes. ISRN Radiol. 2013;2013:174524.
  • Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383–421.
  • Wyss-Coray T, Lin C, von Euw D, et al. Alzheimer’s disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates. Ann N Y Acad Sci. 2000;903:317–323.
  • Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
  • Criscuolo C, Fabiani C, Cerri E, et al. Synaptic dysfunction in Alzheimer’s disease and glaucoma: from common degenerative mechanisms toward neuroprotection. Front Cell Neurosci. 2017;11:53.
  • Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572–580.
  • Liu C-C, Liu C-C, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.
  • Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of Alzheimer’s disease in Spanish population. Neurobiol Aging. 2013;34(6):1711.e15–1711.e17.
  • Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421–430.
  • Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43–51.
  • Verheijen J, Van den Bossche T, van der Zee J, et al. A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease. Acta Neuropathol. 2016;132(2):213–224.
  • Vardarajan BN, Zhang Y, Lee JH, et al. Coding mutations in SORL1 and Alzheimer disease. Ann Neurol. 2015;77(2):215–227.
  • Pottier C, Hannequin D, Coutant S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry. 2012;17(9):875–879.
  • Cuyvers E, De Roeck A, Van den Bossche T, et al. Mutations in ABCA7 in a Belgian cohort of Alzheimer’s disease patients: a targeted resequencing study. Lancet Neurol. 2015;14(8):814–822.
  • Gutierrez-Rodrigues F, Calado RT. The interpretation of rare or novel variants: damaging vs. disease-causing. Rev Bras Hematol Hemoter. 2018;40(1):3–4.
  • Bomba L, Walter K, Soranzo N. The impact of rare and low-frequency genetic variants in common disease. Genome Biol. 2017;18(1):77.
  • Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747–753.
  • Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010;11(6):415–425.
  • Jordan B. [Common and rare variants, polygenic traits and missing heritability]. Med Sci. 2017;33(6-7):674–676.
  • Zhang W, Jiao B, Xiao T, et al. Association of rare variants in neurodegenerative genes with familial Alzheimer’s disease. Ann Clin Transl Neurol. 2020;7(10):1985–1995.
  • Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease. Nature. 2014;505(7484):550–554.
  • Patel D, Mez J, Vardarajan BN, et al. Association of rare coding mutations with Alzheimer disease and other dementias among adults of European ancestry. JAMA Netw Open. 2019;2(3):e191350.
  • Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4–23.
  • Fracassetti M, Griffin PC, Willi Y. Validation of pooled whole-genome re-sequencing in Arabidopsis lyrata. PLoS One. 2015;10(10):e0140462.
  • Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434–443.
  • Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978–1980.
  • Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48(D1):D498–D503.
  • Pasterkamp RJ, Giger RJ. Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol. 2009;19(3):263–274.
  • Good PF, Alapat D, Hsu A, et al. A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer’s disease. J Neurochem. 2004;91(3):716–736.
  • Uchida Y, Ohshima T, Sasaki Y, et al. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer’s disease. Genes Cells. 2005;10(2):165–179.
  • Stoeckli ET. Understanding axon guidance: are we nearly there yet?Development. 2018;145(10):dev151415.
  • Gay CM, Zygmunt T, Torres-Vázquez J. Diverse functions for the semaphorin receptor PlexinD1 in development and disease. Dev Biol. 2011;349(1):1–19.
  • Lu Y, Liu W, Wang X. TREM2 variants and risk of Alzheimer’s disease: a meta-analysis. Neurol Sci. 2015;36(10):1881–1888.
  • Dasdag S, Akdag MZ, Erdal ME, et al. Effects of 2.4 GHz radiofrequency radiation emitted from Wi-Fi equipment on microRNA expression in brain tissue. Int J Radiat Biol. 2015;91(7):555–561.
  • Dasdag O, Adalier N, Dasdag S. Electromagnetic radiation and Alzheimer’s disease. Biotechnol Biotechnol Equip. 2020;34(1):1087–1094.